FindTrial
Sign In

Clinical potential of combined dezocine and sufentanil in postoperative care for the elderly of thyroid cancer

Clinical potential of combined dezocine and sufentanil in postoperative care for the elderly of thyroid cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016328
Enrollment
Unknown
Registered
2018-05-25
Start date
2013-01-01
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

SD group:SD group was set at 0.3 mg/kg dezocine+1.0 µg/kg sufentanil + 8 mg ondansetron + normal saline
S group:the dose was set at 2.0 µg/kg sufentanil + 8 mg ondansetron + normal saline.

Sponsors

Ezhou Central Hospital, Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 77 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the study were clear consciousness, no history of addiction or allergy to opioids, no history of immune or endocrine system disorders, and no history of blood transfusion.

Exclusion criteria

Exclusion criteria: Patients with severe cardiopulmonary diseases (cardiac function of class III or above; pulse oximetry, arterial oxygen saturation (SpO2) 3 times the normal value or creatinine level above normal), and those who received preoperative radiotherapy, chemotherapy, or immunotherapy were all excluded.

Design outcomes

Primary

MeasureTime frame
CD3+;CD4+;CD8+;CD28+;NK cell;C-reactive protein (CRP);VAS (visual analogue scale) scores;adverse reactions;—

Countries

China

Contacts

Public ContactZewen Liu

Ezhou Central Hospital, Wuhan University

andylzw2007@163.com+86 18062308979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026